Welcome to our dedicated page for UTAH MEDICAL PRODUCTS SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UTAH MEDICAL PRODUCTS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UTAH MEDICAL PRODUCTS's regulatory disclosures and financial reporting.
Utah Medical Products reported 2025 revenue of $38.5 million, down 5.8% from 2024, as several key customers reduced orders or exited. Net income fell 18.7% to $11.3 million, and GAAP EPS declined 12.1% to $3.483, reflecting lower sales and higher operating costs.
The sharpest hit came from OEM customer PendoTECH and a Chinese distributor that canceled part of its 2025 order and left a receivable that was written off. Filshie device revenue slipped overall, though U.S. hospital sales grew. Even with these pressures, UTMD maintained gross margin above 57% and ended the year with $85.8 million in cash after paying dividends and repurchasing about 4.5% of its shares.
Utah Medical Products Inc received Amendment No. 2 to a Schedule 13G/A from The Vanguard Group stating that, following an internal realignment effective January 12, 2026, The Vanguard Group reports 0 shares (0%) beneficially owned of the company’s common stock. The filing is signed by Ashley Grim, Head of Global Fund Administration on March 27, 2026, and cites SEC Release No. 34-39538 as the basis for disaggregated reporting by Vanguard subsidiaries.
Utah Medical Products, Inc. furnished an update on its business by providing financial information for the three and twelve months ended December 31, 2025, in a press release dated January 29, 2026. The press release, attached as Exhibit 99.1, also contains forward-looking statements about 2025 and beyond.
The company submitted this information under a current report, stating that the material is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.
Utah Medical Products Inc. director Kevin Timken reported an initial beneficial ownership position that includes a stock option to buy 10,000 shares of the company’s common stock. The option has an exercise price of $58.10 per share, becomes exercisable on 10/01/2026, and expires on 10/31/2035.
The option vests 25% on 10/01/2026, with an additional 6.25% vesting on 01/01/2027 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 10/01/2029. This filing reflects his status as a director and provides transparency into his equity-based compensation.
Utah Medical Products Inc. (UTMD) reported an equity compensation award to its Principal Financial Officer. On 10/31/2025, the officer received an employee stock option to buy 500 shares of UTMD common stock at an exercise price of $58.1 per share. The option expires on 10/31/2035 and will vest 25% on 1/1/27, with an additional 6.25% vesting on 4/1/27 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 1/1/30. Following this grant, the officer beneficially owned 5,600 derivative securities directly.
Utah Medical Products (UTMD) filed its Q3 2025 report showing sales of $9.812M and diluted EPS of $0.82. Gross margin was 57.1% and operating margin 26.6%, both lower year over year as operating income fell 21.9%.
Management cited two outside‑U.S. distributor cancellations/delays that reduced shipments by $976 and revenues by $581, and recorded a $395 bad‑debt reserve tied to a China distributor fee. Non‑operating income eased with lower cash yields. By category, Q3 sales were Gynecology/Electrosurgery/Urology $4.954M (down), Neonatal $2.176M (up), Blood Pressure Monitoring $1.643M (down), and Labor & Delivery $1.039M (flat).
Year to date, sales were $29.475M and EPS $2.68. Cash and investments were $84.267M, current liabilities $3.011M. The company repurchased 130,984 shares for $7.361M and paid $3.006M in dividends. Management now expects 2025 revenue to be 6–7% lower than 2024 and EPS of $3.40–$3.50.
Utah Medical Products (UTMD) expanded its Board from five to six members and appointed Kevin Timken as a director. He will serve on the Audit Committee and the Compensation and Benefits Committee. Timken previously advised UTMD on U.S. SEC matters during a 25-year legal career.
As a director, Timken received 10,000 stock options with an exercise price of $58.10 per share, vesting over four years, and the standard Board fee of $7,650 per quarter, pro‑rated for the final quarter of 2025.
UTMD also increased its regular quarterly cash dividend to $0.31 per share, payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025.
Utah Medical Products, Inc. furnished an update on its results under Item 2.02. The company attached a press release (Exhibit 99.1) with financial information for the three and nine months ended September 30, 2025, along with forward-looking statements for 2025 and beyond.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings.
Brandes Investment Partners, L.P. filed an amendment to Schedule 13G reporting beneficial ownership of 333,204 common shares of Utah Medical Products Inc (UTMD), representing 10.39% of the class. The filing shows Brandes has shared voting power over 286,784 shares and shared dispositive power over 333,204 shares, with no sole voting or dispositive power. The form states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing identifies the reporting person as an investment adviser organized in Delaware and lists principal office at 4275 Executive Square, La Jolla, CA. The signature on the amendment is dated 09/02/2025.
Brian L. Koopman, Principal Financial Officer of Utah Medical Products Inc. (UTMD), reported the sale of 50 shares of the company's common stock on 09/04/2025 at a price of $62.75 per share. Following the reported transaction, Mr. Koopman beneficially owns 832 shares in a direct capacity. The Form 4 is signed by Mr. Koopman on 09/05/2025.